Entity

Time filter

Source Type

Burlingame, CA, United States

Patent
Epitomics Inc. | Date: 2010-07-30

An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target.


Patent
Epitomics Inc. | Date: 2013-01-23

In certain embodiments, the method may comprise: a) obtaining the antibody sequences from a population of B cells; b) grouping the antibody sequences to provide a plurality of groups of lineage-related antibodies; c) testing a single antibody from each of the groups in a bioassay and, after the first antibody has been identified, d) testing further antibodies that are in the same group as the first antibody in a second bioassay. In another embodiment, the method may comprise: a) testing a plurality of antibodies obtained from a first portion of an antibody producing organ of an animal; b) obtaining the sequence of a first identified antibody; c) obtaining from a second portion of said antibody producing organ the sequences of further antibodies that are related by lineage to said first antibody; and, c) testing the further antibodies in a second bioassay.


Patent
Epitomics Inc. | Date: 2013-01-02

The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.


Patent
Epitomics Inc. | Date: 2015-12-17

In certain embodiments, the method may comprise: a) obtaining the antibody sequences from a population of B cells; b) grouping the antibody sequences to provide a plurality of groups of lineage-related antibodies; c) testing a single antibody from each of the groups in a bioassay and, after the first antibody has been identified, d) testing further antibodies that are in the same group as the first antibody in a second bioassay. In another embodiment, the method may comprise: a) testing a plurality of antibodies obtained from a first portion of an antibody producing organ of an animal; b) obtaining the sequence of a first identified antibody; c) obtaining from a second portion of said antibody producing organ the sequences of further antibodies that are related by lineage to said first antibody; and, c) testing the further antibodies in a second bioassay.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 99.60K | Year: 2005

DESCRIPTION (provided by applicant): The objective of this proposal is to develop a novel technology for detecting multiple protein markers for disease management. In this project, the technology will be used in profiling the phosphorylation state of numerous proteins in a single test. Most clinical tests currently in use are based on the detection of single disease markers, which limits their accuracy. In contrast, a single test to evaluate multiple disease markers would significantly enhance the analytical and predictive powers of disease testing. Therefore, developing a high throughput and cost effective technology for multi-marker detection is an urgent, unmet, medical need. Recent research suggests that certain protein phosphorylation events are likely to occur during specific diseased states. This program will develop a high throughput protein detection technology, Epitope-based Quantification Using Antibodies and T7-polymerase (EpiQUANT), for determining the phosphorylation patterns of numerous proteins at once in normal and diseased tissue samples. The diagnostic potential of EpiQUANT technology will be evaluated using clinical samples. Until now, most phospho-specific antibodies have been polyclonal in nature, which severely limits their diagnostic utility. The advent of Epitomics' rabbit monoclonal antibody (RabMAb) technology enables, for the first time, the reliable production of monoclonal phospho-specific antibodies with consistent quality and an unlimited supply. EpiQUANT will represent a new level of throughput through the novel, synergistic combination of two proven technologies-antibody binding and DNA microarray detection. If successfully developed, EpiQUANT technology and diagnostic kits will enable the simultaneous, systematic analysis of phosphorylated proteins and relate these patterns directly to diseased versus healthy states. These reagent kits will be commercialized to the research community and further developed into diagnostic products.

Discover hidden collaborations